Tesofensine: The Triple Monoamine Reuptake Inhibitor Studied for Obesity

A quick clarification before anything else, because it matters for how you file this one: tesofensine is not a peptide. It is a small-molecule drug, an oral compound, not an injectable peptide like the GLP-1 agonists it often gets compared to. We log it here because it keeps surfacing in weight-loss discussions alongside peptides, and the confusion is worth clearing up rather than leaving to marketing copy.

What it is, mechanistically

Tesofensine is a centrally acting triple monoamine reuptake inhibitor. It blocks the reuptake of three neurotransmitters at once: noradrenaline (norepinephrine), dopamine, and serotonin. By slowing their reabsorption, it raises their signaling in the brain, and all three are involved in appetite, food-seeking behavior, and metabolic regulation. In diet-induced obese rat models, appetite suppression appeared to be driven indirectly through alpha-1 adrenoceptor and dopamine D1 receptor pathways.

The drug has an unusual origin story. It was originally developed by NeuroSearch for neurodegenerative conditions (Parkinson's and Alzheimer's research). It underperformed there, but investigators noticed unintended weight loss in treated patients, and the program pivoted toward obesity. The asset is now held by Saniona.

The trial evidence (TIPO program)

The most-cited human data is the Phase 2 trial published in The Lancet in 2008 (Astrup et al.), part of the TIPO program. The design, as reported:

The headline results: diet plus placebo produced about 2.0% weight loss. Tesofensine plus diet produced 4.5%, 9.2%, and 10.6% at the 0.25, 0.5, and 1.0 mg doses respectively — all significantly greater than placebo. The 0.5 mg dose, the one framed as the likely recommended dose, delivered roughly 10% placebo-adjusted weight loss over 24 weeks, which at the time was around double what then-approved anti-obesity drugs achieved.

Two caveats belong in the same breath as those numbers. First, these are Phase 2 results in about 200 people over six months — encouraging, not definitive. Sponsor material references subsequent Phase 3 work confirming efficacy and safety, but the peer-reviewed, widely scrutinized dataset most people are actually citing is that 2008 Phase 2 trial. Second, in an unusual move, The Lancet issued an expression of concern about the study in 2013. That does not erase the data, but it is a flag an evidence-first reader should carry forward rather than ignore.

The cardiovascular question

This is the recurring theme in tesofensine's story, and it follows directly from the mechanism. Raising noradrenaline and dopamine signaling tends to raise heart rate and blood pressure. In the Phase 2 trial, heart rate increased by 7.4 beats per minute in the 0.5 mg group (p=0.0001). The authors reported no significant blood pressure increase at the 0.25 and 0.5 mg doses versus placebo — but a published commentary pushed back, noting that tesofensine appeared to raise both systolic and diastolic blood pressure by roughly 4-6 mm Hg when compared against a similar amount of weight loss achieved by lifestyle change alone.

That cardiovascular signal is widely cited as the central reason US development did not advance. It also explains a specific formulation choice: Tesomet combines tesofensine with metoprolol, a beta-blocker, explicitly to blunt the heart-rate and blood-pressure effects.

Regulatory status: not FDA-approved

Straightforwardly: tesofensine is not approved by the US FDA for obesity or anything else. If you want to see how we track approval states generally, our FDA status reference lays out the categories.

The more active regulatory story is in Mexico, where Saniona's partner Medix pursued authorization through COFEPRIS. In February 2023, COFEPRIS's technical committee on new molecules issued a favorable opinion on tesofensine for obesity. Reporting on the final approval has been mixed and evolving — including later signals (around late 2024) that full authorization was still pending or complicated — so the honest summary is: a favorable regulatory opinion in one country, an evolving status, and no US approval. Verify the current state against primary regulatory sources before relying on any single claim, including this one.

How to hold it next to the GLP-1s

The comparison to drugs like semaglutide is where tesofensine gets oversold. The mechanisms are entirely different — a small-molecule monoamine reuptake inhibitor versus an injectable GLP-1 receptor agonist peptide — and the depth of evidence is not remotely comparable. GLP-1 agonists carry large, long, cardiovascular-outcome-inclusive trial programs and regulatory approvals. Tesofensine's most-cited human efficacy data remains a single six-month Phase 2 trial that itself drew an expression of concern, paired with an unresolved cardiovascular safety question.

That is the whole point of logging it this way: real signal on weight loss, a mechanistically predictable safety flag, and a regulatory status that is anything but settled.

PepStash is a research log and reference tool. This article is educational and is not medical advice — it does not diagnose, treat, or recommend any protocol. Regulatory status and trial data change; always verify against primary sources and consult a licensed physician before making any decisions about your health.